Bitcoin ETFs add $186M as Morgan Stanley's MSBT inflows top $100M in first six trading days
U.S. spot bitcoin exchange-traded funds recorded their second consecutive day of net inflows on Wednesday, adding $186.1 million following the prior session's $411.5 million influx.
The 13-fund group has now accumulated around $57.1 billion since the ETFs first launched in January 2024, with total net assets reaching $97.6 billion as of April 15, or 6.5% of bitcoin's market capitalization, according to SoSoValue.
Only two funds posted positive flows on Wednesday, including BlackRock's IBIT, which led all products with $291.9 million, its largest single-day inflow since the beginning of April. Morgan Stanley's MSBT ranked second with $19.3 million.
Notably, Morgan Stanley’s MSBT has eclipsed a primary competitor within its first week of operations. Just six trading days after its market debut, MSBT reached more than $103 million in total net inflows, moving past the $86 million cumulative total held by the WisdomTree Bitcoin Fund, according to Farside.
Meanwhile, eight funds recorded zero net flows on the day. Fidelity's FBTC saw $47.4 million in outflows, while Ark Invest and 21Shares' ARKB and Grayscale's GBTC posted redemptions of $42.2 million and $23.4 million, respectively. Bitwise's BITB and VanEck's HODL recorded smaller outflows of $8.5 million and $3.7 million, SoSoValue data shows.
Bitcoin traded above $74,600 on Thursday. The benchmark cryptocurrency has gained 3% over the past week and 23% since hitting a low near $60,000 on Feb. 6. The price remains 41% below the all-time high of approximately $126,000 set on Oct. 6, 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
